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DECISION MAKING AND PROBLEM SOLVING
Introduction
During the last decades, survival of patients treated for classi-
cal Hodgkin’s lymphoma (HL) has improved substantially and, to
date, the overall cure rate for this neoplasm is about 80-85%.1
Improvement in the outcome is mostly due to the development
of more active chemotherapy (CT) regimens, of a more accurate
radiotherapy (RT) and of a rational combination of the different
treatment modalities. Unfortunately, however, the risk of treat-
ment-related morbidity and mortality is still significant,2,3 and
modern therapies should attempt to maximize the chance of
cure, while minimizing late toxicity. In order to offer the best
available treatment to patients with lymphoma, the Italian
Society of Haematology (SIE), the Italian Society of Experimental
Haematology and the Group for Bone Marrow Transplantation
(GITMO) supported the development of clinical practice guide-
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The Italian Society of Hematology (SIE), the Italian Society of Experimental Haematology (SIES) and the Italian Group
for Bone Marrow Transplantation (GITMO) commissioned a project to develop practice guidelines for the initial work-
up, therapy and follow-up of classical Hodgkin’s lymphoma. Key questions to the clinical evaluation and treatment of
this disease were formulated by an Advisory Committee, discussed and approved by an Expert Panel (EP) composed of
senior hematologists and one radiotherapist. After a comprehensive and systematic literature review, the EP recommen-
dations were graded according to their supporting evidence. An explicit approach to consensus methodologies was used
for evidence interpretation and for producing recommendations in the absence of a strong evidence. The EP decided that
the target domain of the guidelines should include only classical Hodgkin’s lymphoma, as defined by the WHO classifi-
cation, and exclude lymphocyte predominant histology. Distinct recommendations were produced for initial work-up,
first-line therapy of early and advanced stage disease, monitoring procedures and salvage therapy, including hemopoiet-
ic stem cell transplant. Separate recommendations were formulated for elderly patients. Pre-treatment volumetric CT
scan of the neck, thorax, abdomen, and pelvis is mandatory, while FDG-PET is recommended. As to the therapy of early
stage disease, a combined modality approach is still recommended with ABVD followed by involved-field radiotherapy;
the number of courses of ABVD will depend on the patient risk category (favorable or unfavorable). Full-term chemother-
apy with ABVD is recommended in advanced stage disease; adjuvant radiotherapy in patients without initial bulk who
achieved a complete remission is not recommended. In the elderly, chemotherapy regimens more intensive than ABVD
are not recommended. Early evaluation of response with FDG-PET scan is suggested. Relapsed or refractory patients
should receive high-dose chemotherapy and autologous hemopoietic stem cells transplant. Allogeneic transplant is rec-
ommended in patients relapsing after autologous transplant. All fertile patients should be informed of the possible effects
of therapy on gonadal function and fertility preservation measures should be taken before the initiation of therapy. 
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lines for initial work-up, therapy and follow-up of the dif-
ferent lymphoma categories. Three of these guidelines
have already been published, namely for nodal indolent
lymphoma,4 nodal diffuse large B-cell lymphoma,5 and
extranodal lymphoma of the lung and mediastinum.6 The
guidelines produced for initial work-up, treatment and fol-
low-up of patients with classical HL are illustrated in this
paper. 
Design and Methods
Organization and design
The organization and design of this project have been
reported in a previous paper on guidelines for the manage-
ment of nodal indolent non-Hodgkin’s lymphoma.4 The
first search of evidence databases was performed in May
2007 and updated throughout the project. The full refer-
ence list (including abstracts of full papers) is available
from marchettim@smatteo.pv.it.
The grading system chosen for present guidelines is that
developed by the Scottish Intercollegiate Guidelines
Network (SIGN). Recommendations are therefore graded
as grade A if supported by consistent and applicable level
1 evidence (at least one level 1++ trial or some consistent
level 1+ trials), as grade B if derived from consistent results
of level 2++ studies or extrapolated from level 1+/1++ tri-
als, as grade C if supported by grade 2+ studies that could
be applied directly to the object population and provided
consistent results, or level 1++ studies from different pop-
ulations (translated evidence), and as grade D when sup-
ported by poor quality evidence or evidence extrapolated
from level 2+ studies, and thus sustained mainly by
experts’ opinion. Updating of the present guidelines is
expected within two years. 
Definitions
The Expert Panel (EP) agreed on the following defini-
tions that are used in these guidelines: 
Histological variants of Hodgkin’s lymphoma and age categories
Two histological variants of HL have been defined by
the WHO classification:7 the classical variant that includes
nodular sclerosis, mixed cellularity, lymphocyte-rich and
lymphocyte depletion histologies and the nodular lympho-
cyte predominant variant. In the first consensus meeting,
the EP agreed to address only the classical and to exclude
the lymphocyte predominant variant. HL developing in
HIV-positive patients was also excluded. 
Staging
Staging terminology is according to the Ann Arbor crite-
ria, modified at the Cotswolds meeting.8 These criteria are
illustrated in Table 1 and define limited (early stage) and
advanced disease. Early stage disease includes patients
with clinical stage I and II, further subdivided according to
the EORTC criteria9 into favorable and unfavorable sub-
groups (Table 2). 
Risk scoring system for advanced disease
The scoring system for advanced stage we will refer to
in the text is that defined by Hasenclever et al.10 In this sys-
tem, the variables with an adverse prognostic impact are:
age > 45 years, male gender, stage IV, Hb <10.5 g/dL, albu-
min <4 g/dL, leukocytes ≥15×109/L, lymphocytes
<0.6×109/L (or <8% in the differential count). Table 3 indi-
cates the percent of patients belonging to each prognostic
group in the original cohort, with the respective 5-year
progression free survival (PFS). 
Response assessment
The response criteria utilized in this paper are those
updated by Cheson et al.11 and illustrated in Table 4. 
Radiotherapy
Table 5 defines the fields of irradiation in the different
types of radiotherapy. 
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Table 1. The Ann Arbor/Cotswolds staging system.
Stage Involvement
I Single lymph node region (I) or one extralymphatic site (IE)
II Two or more lymph node regions on the same side of the
diaphragm (II) or local extralymphatic extension plus one or
more lymph node regions on the same side of the diaphragm (IIE)
III Lymph node regions on both sides of the diaphragm (III), 
which may be accompanied by local extralymphatic extension (IIIE)
IV Diffuse involvement of one or more extralymphatic 
organs or sites
A: no systemic symptoms. 
B: presence of at least one of these symptoms: unexplained weight
loss> 10% baseline during the six months prior to staging; recurrent
unexplained fever >38°C; recurrent night sweats.
Bulky tumor: either a single mass exceeding 10 cm in the largest 
diameter or a mediastinal mass exceeding one third of the maximum
transverse trans-thoracic diameter measured on a standard 
posterior-anterior chest X-ray at the level of the T5-T6 intervertebral
disk.
Table 2. Early stage Hodgkin’s lymphoma: favorable and unfavorable
subgroups according to EORTC criteria. 
Subgroup Prognostic factors
Favorable
Stage I and II with ≤3 nodal involved areas, 
and age <50 years, and M/T ratio <0.33,
and ESR <50 without B symptoms, 
or ESR <30, with B symptoms
Unfavorable
Stage II with ≥4 nodal involved areas,
or age ≥50 years, or MT radio ≥0.33
or ESR ≥50 without B symptoms, or ESR ≥30
with B symptoms
ESR: Erythrocyte Sedimentation Rate; M/T: mediastinum/thorax.
Table 3. International Prognostic System for advanced stage
Hodgkin’s lymphoma.1
N. of risk factors2 % of total 5-yr FFP %
0 7 84
1 22 77
2 29 67
3 23 60
4 12 51
≥5 7 42
FFP: freedom from progression. 1According to Hasenclever et al.N Engl J Med,1998.
10
2For description of risk factors,see Design and Methods (Risk scoring system).
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Results
Initial work-up
The EP addressed the issue of which tests and evalua-
tions should be carried out before the start of therapy (ini-
tial work-up), in order to choose the more appropriate
treatment strategy and to allow for adequate response
evaluation. Initial work-up for HL has evolved over the last
40 years. As long as irradiation was the main therapy, the
most accurate assessment of the initial disease extension
was essential; this requirement, in the absence of accurate
imaging techniques, led in the 70s to the application of
invasive procedures such as staging laparotomy with
splenectomy and bipedal lymphangiography. In the 80s,
the increased role of chemotherapy, the lesser extension
and intensity of RT, and the assessment of the adverse
effects of laparotomy with splenectomy (0.5% mortality,
10% morbidity with an increased risk of secondary
leukemia)12 led to the abolishment of laparotomy from the
initial disease inventory of HL. In the meantime, both the
availability and accuracy of imaging techniques have
improved substantially, with the introduction of high-reso-
lution computed tomography (CT scan), nuclear magnetic
resonance (NMR), positron emission tomography with flu-
oro-deoxyglucose (FDG-PET), and the combination of CT
scan and PET imaging (CT-PET). In particular, high-resolu-
tion CT scan has brought the advantage of eliminating the
influence of respiratory motion, of a higher scanning
speed, and of whole body scanning during the peak con-
trast enhancement (in the ideal conditions, spiral CT can
detect lymph nodes of 5-7 mm of diameter). Randomized
trials on comparative efficacy of these modern techniques
for the best initial work-up of HL are lacking; therefore,
recommendations on this matter can only be derived from
consensus among experts. 
The EP indicated the methods to define the initial exten-
sion of disease and the tests to evaluate co-morbidities
and/or particular clinical conditions. As to the first catego-
ry, all patients affected with classical HL should undergo at
diagnosis a complete blood count, renal and liver function
tests, serum albumin and lactic dehydrogenase determina-
tions, and erythrocyte sedimentation rate evaluation. The
initial extension of disease should be evaluated through a
volumetric CT scan of neck, thorax, abdomen, and pelvis
and the presence of systemic symptoms must be carefully
assessed according to the classical criteria. Antero-posteri-
or chest X-ray, with calculation of the ratio of mass to tho-
rax diameters, is necessary to define mediastinal involve-
ment as bulky or not. In patients with B symptoms and/or
advanced stage disease and/or blood count abnormalities,
monolateral bone marrow biopsy should be performed. As
to the co-morbidities, patients should be tested for HBV,
HCV and HIV. Cardiac function should be evaluated with
ultrasound bidimensional measurement of left ventricular
Table 4. Up-dated response criteria for lymphoma.1
Type of Definition Lymph nodes Spleen, liver Bone marrow 
response
Complete remission
Disappearance of all Masses of any size permitted Not palpable; nodules Infiltrate cleared on 
evidence of disease if FDG-PET negative disappeared repeated biopsy
Partial remission
Regression of ≥50% decrease in SPD of up to ≥ 50% decrease in SPD 
measurable disease six largest masses; no increase of nodules; no increase
and no new sites in size of other nodes. in size of liver or spleen
One or more FDG-PET positive at 
previously involved sites
Stable disease
Failure to attain CR FDG-PET positive at prior sites of 
or PR disease and no new sites on CT scan
or FDG-PET 
Relapse or progression 
Any new lesion or Appearance of a new lesion or ≥50% ≥50% increase in the New or recurrent 
increase by ≥50% of increase in longest diameter of a SPD of any previous involvement
previously involved previous node≥ lesion
sites New FDG-PET positive lesion
FDG: fluorodeoxyglucose; PET: positron emission tomography; PR: partial response; CR: complete remission; CT: computed tomography; SPD: sum of the product of
diameters. 1Modified from Cheson et al. J Clin Oncol, 2007.11
Table 5. Radiotherapy fields.
Definitions Fields of irradiation
Involved nodal Initially involved lymph nodes
Involved field Initially involved nodal regions (cervical, mediastinum,
supraclavicular, axilla, para-aortic, spleen, iliac, 
inguinal)
Extended field Initially involved and contiguous nodal regions 
Mantle Bilateral cervical, supraclavicular, infraclavicular,
axillary nodes, and mediastinum (including the
bilateral hylar regions) ± the spleen
Subtotal nodal Mantle + Para-aortic nodal regions
Inverted Y Para-aortic, iliac and inguinal node regions
Total nodal Mantle + Inverted Y
ejection fraction; this procedure is simpler and less expen-
sive than angio-scintigraphy in detecting even slight
abnormalities of left ventricular function. Women of fertile
age should undergo a pregnancy test before starting thera-
py. Thyroid function assessment through TSH, FT3 and
FT4 evaluation is recommended in candidates for neck
irradiation, together with accurate dental survey and care.
Pregnancy tests in women and fertility counseling to
patients of reproductive age are also recommended. 
A further issue was raised by the EP on the clinical appli-
cation of FDG-PET scan before the initiation of therapy.
Should baseline FDG-PET scan be performed in all
patients with HL? Should CT-PET be preferred to PET
scan? The panel indicated that FDG-PET scan before the
initiation of therapy (baseline FDG-PET) is strongly rec-
ommended, although not mandatory. Baseline FDG-PET
is necessary for a PET-aided response assessment during
treatment and, when available, the combined CT-PET is to
be preferred to standard FDG-PET. The EP put a warning
on the risk of upstaging through CT-PET and recommend-
ed that for investigational purposes, FDG-PET images
should be centrally reviewed, preferably in the Digital
Imaging and Communications in Medicine (DICOM) for-
mat. 
Recommendations 
• The following initial evaluations should be performed in all
patients [grade D]: 
(i) assessment of systemic symptoms;
(ii) whole blood count;
(iii) serum albumin;
(iv) serum LDH;
(v) erythrocyte sedimentation rate;
(vi) HBV, HCV and HIV serology;
(vii) standard chest X-ray, with mass to thoracic diameter ratio;
(viii) CT scan of the neck, thorax, abdomen and pelvis;
(ix) bidimensional ultrasound evaluation of left ventricular ejec-
tion fraction;
(x) pregnancy test in women of fertile age.
• Monolateral bone marrow biopsy should be performed in
patients with B symptoms and/or stage III/IV disease and/or
blood count abnormalities [grade D].
• Whole body FDG-PET or CT-PET is recommended
[grade C].
• Dental care and thyroid function (FT3, FT4, TSH) assess-
ment should be performed in patients candidate to neck irradia-
tion [grade D].
• Reproductive counseling should be offered to all patients of
fertile age [grade D].
First-line therapy for early stage disease
The main issue addressed by the EP concerned the best
initial therapeutic approach. To reach their conclusions,
the experts extensively analyzed large randomized clinical
trials conducted in the last 15 years, whose results have
been published as full papers13-21 or as abstracts.22-25 A num-
ber of cohort studies,3,26,27 and the results of Cochrane
analysis on chemotherapy, RT and combined modality for
HL28 have also been considered. For decades, RT has been
the standard of care for patients with early stage HL.
However, the significant risk of relapse after RT alone
(even in favorable subgroups) and the abandonment of
staging laparotomy have substantially reduced the role of
RT as the sole treatment in early stage Hodgkin’s lym-
phoma. The results of large randomized studies compar-
ing RT alone versus combined modality therapy (CMT)
have recently been published.13-16 These studies include a
SWOG trial,13 the German Hodgkin Study Group (GHSG)
HD7 trial,14 and the EORTC H7 and H8 studies.15,16 The
SWOG study has compared subtotal nodal irradiation
(STNI) with a combined modality therapy consisting of
chemotherapy (three courses of doxorubicin and vinblas-
tine) followed by STNI. The 5-year freedom from progres-
sion (FFP) was significantly longer in the CMT compared
to the RT alone group (93 vs. 70%). Likewise, the GHSG
HD7 trial has demonstrated that CMT with two courses
of ABVD (doxorubicin, bleomycin, vinblastine and dacar-
bazine) followed by extended-field radiotherapy (EF-RT)
is superior to EF-RT alone in patients with early stage
favorable Hodgkin’s lymphoma. In the EORTC trials H7
and H8, RT alone was compared to CMT in favorable
patients. In the H7 trial, STNI was randomly compared to
six courses of EBVP (epirubicin, bleomycin, vinblastine
and prednisone) followed by IF-RT. The results of this trial
indicated that the combination of EBVP and IF-RT could
replace STNI as standard treatment. In the H8 trial, favor-
able patients were randomly assigned to either STNI alone
or three courses of MOPP-ABV (mechlorethamine, vin-
cristine, procarbazine, and prednisone alternated to dox-
orubicin, bleomycin, and vinblastine) plus IF-RT. The
CMT proved to be superior to RT alone in terms of disease
control and overall survival. Sufficient data allow the con-
clusion that RT alone may no longer be recommended. 
A number of randomized studies have compared dif-
ferent CT regimens combined with different RT sched-
ules.15-19 In the H7-U trial,15 unfavorable patients were ran-
domly assigned to six courses of EBVP+IF-RT or to six
courses of MOPP-ABV+IF-RT; the latter combination
proved to be significantly superior. In the H8-U trial,16 six
courses of MOPP-ABV+IF-RT were compared to four
courses of MOPP-ABV+STNI, and to four courses of
MOPP-ABV+IF-RT. The 5-year event-free survival rates
were similar in the three groups (84, 87 and 88%, respec-
tively); these results are in favor of a reduction from six to
four courses of chemotherapy in this category of patients
to limit toxicity. 
Radiation field size has prospectively been studied in
the combined modality approach. The HD8 GHSG trial17
has shown in unfavorable patients that, after two courses
of COPP (cyclophosphamide, vincristine, procarbazine,
prednisone) alternated with ABVD, IF-RT (30 Gy) was
equally effective and less toxic when compared to EF-RT
(30 Gy). A randomized study from the Milan Cancer
Institute18 reinforced this notion comparing IF-RT versus
EF-RT after four courses of ABVD. These studies have
clearly demonstrated that the efficacy of IF-RT was not
inferior to EF-RT in terms of relapse-free survival (RFS),
FFP and overall survival (OS), even in unfavorable patients,
with significantly lower toxicity. The EP has therefore
concluded that four courses of ABVD followed by IF-RT
may be considered the standard treatment of limited dis-
ease and that the recommended dose of irradiation is 30
Gy. In the four-arm randomized HD10 and HD11 tri-
als,22,23 the GHSG is comparing the efficacy of different
Guidelines for Hodgkin’s lymphoma
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amounts of CT followed by different IF-RT doses. Results
of an interim analysis have recently been presented in the
abstract form. In favorable patients,22 four courses of
ABVD followed by IF-RT (30 or 20 Gy) were compared
with two courses of ABVD followed by IF-RT (30 or 20
Gy); in unfavorable patients,23 four courses of ABVD fol-
lowed by +IF-RT (30 or 20 Gy) were compared to four
courses of standard-dose BEACOPP (bleomycin, etopo-
side, doxorubicin, cyclophosphamide, vincristine, procar-
bazine, prednisone) + IF-RT (30 or 20 Gy). No differences
between the four arms have so far been observed, either in
favorable or unfavorable groups. The EP has therefore sug-
gested that a further reduction compared to the standard of
both chemotherapy and RT may be tested, but only in a
controlled clinical trial setting. 
The H9-U EORTC study is trying to identify the best CT
regimen to use in a combined modality approach in unfa-
vorable patients.24 This randomized study compares four
versus six courses of ABVD versus four courses of standard
BEACOPP followed by IF-RT (30-36 Gy). Interim results
indicate equivalent efficacy for the three arms, with less
toxicity for ABVD compared to BEACOPP. 
Hodgkin’s lymphoma survivors who have been treated
with chest RT are at increased risk of cardiovascular and/or
pulmonary complications.29-32 Late toxicity of RT may
include coronary alterations, myocardial and pericardial
fibrosis, valvular abnormalities, conduction disturbances,
and pulmonary fibrosis, with restrictive syndrome; the risk
of toxicity is significantly enhanced by the combination of
RT with CT containing doxorubicin and bleomycin. In the
attempt to avoid RT-related toxicity, randomized studies
have compared CT alone to combined modality therapy in
patients with non-bulky early-stage Hodgkin’s lym-
phoma.20,21,25 Besides, CT alone with ABVD has been uti-
lized in a Spanish phase II trial.26 In the Memorial Hospital
study,20 six courses of ABVD alone have been compared to
six courses of ABVD followed by IF-RT (36 Gy); no signif-
icant differences in remission duration, FFP or OS were
found between the two arms. A study from the National
Cancer Institute of Canada and Eastern Cooperative
Oncology Group21 has compared ABVD alone (four to six
courses) to a strategy including chemotherapy and radia-
tion therapy and found no difference in OS; 5-year FFP was
slightly superior in patients given adjuvant RT; however,
this advantage was counteracted by deaths from causes
other than progression of Hodgkin’s lymphoma. Finally,
the EORTC H9-F trial25 has compared EBVP alone with
EBVP+IF-RT (20 Gy) or EBVP+IF-RT (36 Gy) in favorable
patients. The 4-year event-free survival was 69% for EBVP
alone vs. 85% and 87% for EBVP+20 Gy or 36 Gy IF-RT,
respectively. 
Based on the results of these trials, the EP agreed that, at
the moment, there is no evidence of non-inferiority for CT
alone compared to combined modality therapy, and for-
warded these recommendations.
Recommendations
• Patients with favorable early stage disease, according to the
EORTC criteria, should receive chemotherapy with 3 to 4 courses
of ABVD, followed by involved-field radiotherapy. The recom-
mended dose of irradiation is of 30 Gy [grade A].
• Shortened chemotherapy with 2 courses of ABVD followed by
low-dose (20 Gy) IF-RT can be offered to favorable patients in a
clinical trial setting [grade B].
• Patients with unfavorable early stage disease, according to the
EORTC criteria, should receive chemotherapy with 4 to 6 courses
of ABVD followed by involved-field radiotherapy (30 Gy, with
additional 6 Gy to the bulk) [grade B].
First-line therapy for advanced stage disease
The questions addressed by the EP concerned the opti-
mal up-front therapy, the type and number of courses of
CT, and the possible role of RT. To reach their conclusions,
the experts have analyzed the results of randomized clini-
cal trials, either as full papers33-45 or abstracts,46-48 and of
meta-analyses of randomized clinical trials.49,50
Evidence for the efficacy of chemotherapy to cure
advanced Hodgkin’s lymphoma has derived from studies
initiated more than 35 years ago, with the introduction
into the clinical practice of MOPP (mechlorethamine, vin-
cristine, procarbazine, prednisone) chemotherapy.51 The
25-year updated results of MOPP regimens indicate a cure
rate of about 50%.52 After the introduction of the ABVD
chemotherapy, a randomized study33 demonstrated that
MOPP+RT+MOPP was inferior to ABVD+RT+ABVD and
two randomized studies34,35 that MOPP alone was inferior
in terms of failure free survival compared to the alternating
use of MOPP and ABVD. The alternating MOPP and
ABVD approach has therefore become the standard of
therapy; randomized trials failed to demonstrate any dif-
ference between the alternating and the hybrid modali-
ty.36,37
In a US intergroup trial,38 ABVD alone has subsequently
been shown to be superior to MOPP alone and to be equiv-
alent to the alternating MOPP and ABVD; hence, the
ABVD has become the preferred induction therapy in
advanced Hodgkin’s lymphoma. Up-front ABVD has fur-
ther been tested versus the hybrid MOPP/ABV in a US
trial,39 versus the Stanford V regimen and the
MOPP/EBV/CAD program in an Italian co-operative
study,40 and versus alternating or hybrid multi-drug regi-
mens such as ChlVPP/PABlOE and ChlVPP/EVA in a UK
study.41 In all these trials, hybrid regimens did not show
any superiority over ABVD alone which therefore emerged
as the best regimen based on equivalent efficacy and lower
toxicity. This conclusion, however, is challenged by a 37%
failure rate after ABVD and an 18% death rate in a median
follow-up of five-years (about half of total deaths were due
to progressive disease).39 Meanwhile, the 15-year updated
CALGB study has shown for the ABVD group a 50% fail-
ure-free and a 65% overall survival,42 the mature results of
the Stanford V regimen have been published,53 and an
Intergroup trial has compared Stanford V vs. ABVD±RT
(this study has been closed to accrual for one year and
results are pending). 
The BEACOPP regimen (bleomycin, etoposide, adri-
amycin, cyclophosphamide, vincristine, procarbazine,
prednisone) has been introduced by the German Hodgkin
Study Group in its baseline and dose-escalated variants,
with a substantial increase of dose-density and dose-inten-
sity compared to ABVD and hybrid regimens. In the HD9
randomized trial,43 alternating COPP and ABVD have been
compared with baseline and dose-escalated BEACOPP.
Radiotherapy (36 Gy) was administered on sites of bulky
disease or on residual disease after chemotherapy. At five
years, a significant superiority was demonstrated in free-
dom from treatment failure (FFTF) and OS for dose-esca-
lated BEACOPP (87%) versus baseline BEACOPP (76%)
and the alternating COPP/ABVD (69%) program. Dose-
escalated BEACOPP was associated with a significantly
greater toxicity compared to baseline BEACOPP and
COPP/ABVD. The 10-year up-date of the HD9 study46
confirms that BEACOPP escalated chemotherapy pro-
duced a significant improvement in long-term FFTF and
OS compared to both COPP/ABVD and baseline BEA-
COPP and this advantage is particularly evident in the sub-
set of poor prognosis patients, as defined by the
International Prognostic Score.10
Only a direct comparison between ABVD and BEA-
COPP may indicate the gold standard therapy for
advanced stage Hodgkin’s lymphoma. A number of ran-
domized studies are being conducted to compare ABVD
with BEACOPP; at the moment, however, only data in the
form of Abstracts are available.47,48 The preliminary results
of the HD2000 trial,47 suggest a superiority of BEACOPP
over ABVD in terms of FFP but not of OS. In the IIL-
GITIL-Michelangelo study,48 ABVD (6-8 courses) or BEA-
COPP (4 escalated+4 baseline) first-line chemotherapy,
plus pre-planned high-dose salvage, produced a compara-
ble 3-year outcome. BEACOPP as up-front therapy scored
a superior 3-year FFP (87 vs. 71%); however, freedom from
second progression (92 vs. 87%) and OS (90 vs. 91%) were
comparable to ABVD as up-front therapy. Altogether, no
significant differences have so far emerged in the OS
between ABVD and more intensive regimens, even
though differences favoring dose intensive programs have
been observed in the CR rate and progression free sur-
vival. The EP concluded that there is not yet any direct evi-
dence that BEACOPP produces a significantly longer over-
all survival compared to ABVD. 
Number of courses
There are no randomized trials on the optimal number
of courses of CT in advanced disease. The US Intergroup
study38 demonstrated that 6-8 courses of ABVD were
equivalent to 12 courses of the alternating MOPP and
ABVD regimens, and indicated 6-8 courses of ABVD as
the standard amount of CT. However, both the EORTC-
GELA using ABVD and the GHSG using BEACOPP con-
sider that 8 courses still remain the standard. A random-
ized comparison between 6 and 8 courses has not been
conducted and 6 courses cannot at the moment be consid-
ered the standard for all patients with advanced stage dis-
ease. The EP concluded that there are no reasons to
administer more than 8 courses of ABVD and recom-
mends 6-8 courses; the choice of limiting to 6 the total
number of courses will be prospectively supported by the
demonstration of early FDG-PET-negativity (after two
cycles of ABVD). 
The role of RT
A meta-analysis of 16 randomized studies indicated a
potential advantage of IF-RT after MOPP or MOPP-like
regimens, whereas this advantage was not evident after
ABVD or ABVD-like regimens, either in terms of RFS or
OS.49,50 A randomized EORTC study44 demonstrated that
consolidation with IF-RT did not improve the outcome in
patients in complete remission after 6-8 courses of alter-
nating MOPP and ABV, and a randomized GELA trial45
that consolidation with IF-RT was not superior to two
additional cycles of chemotherapy. The EP concluded that
in patients achieving complete remission with chemother-
apy, additional radiotherapy does not improve the overall
results. Even the utility of irradiation to areas of initial
bulky disease in patients achieving complete remission
with adequate anthracycline-containing regimens is con-
troversial. The value of FDG-PET scan may emerge as a
means to select patients to be irradiated; at the moment,
however, the EP did not reach a consensus. 
Recommendations
• Patients with advanced stage disease should receive 6-8
courses of ABVD as first-line therapy [grade A].
• The use of MOPP or MOPP-like regimens is not recom-
mended; nor is the use of alternating or hybrid regimens (MOPP-
ABVD; MOPP-ABV; MOPP-EBV-CAD; ChLVPP-EVA;
ChlVPP-PABIOE) [grade A].
• First-line escalated BEACOPP cannot be recommended as a
standard, but only in controlled clinical trials. This recommenda-
tion is based on the currently available limited evidence of supe-
riority compared to ABVD and because of a significantly higher
toxicity [grade B].
• Patients without initial bulky disease achieving CR with
anthracycline-containing chemotherapy should not receive adju-
vant radiotherapy [grade A].
• A consensus on the utility of adjuvant radiotherapy to areas
of initial bulk in patients achieving CR with anthracycline-con-
taining chemotherapy was not reached.
Treatment of elderly patients
The less favorable prognosis of Hodgkin’s lymphoma in
the elderly is mostly due to the higher toxicity induced by
treatment in an advanced age compared to younger
patients; this substantially impairs the dose intensity of
chemotherapy and eventually lessens its efficacy.54,55
Moreover, cardiovascular, respiratory and/or metabolic
co-morbidities are important determinants of the less
favorable prognosis of Hodgkin’s lymphoma in the elder-
ly.56,57 The EP defined as elderly patients over 70 years and
addressed the question of whether a conventional strate-
gy or a reduced-intensity approach is more appropriate for
this category of patients. 
Hodgkin’s lymphoma is infrequent in the elderly and
prospective randomized studies in this group of patients
are lacking. The EP recommendations are, therefore, based
on the analysis of retrospective studies or on data extract-
ed from sub-groups of elderly patients enrolled into trials
originally designed for younger patients. Data extrapolat-
ed from the HD8 GHSG study58 indicate that in patients
with early stage disease, without co-morbidities, 2-4
courses of chemotherapy with ABVD followed by limited
radiotherapy are well tolerated and produce a high com-
plete remission rate. Extended RT has a negative impact in
elderly patients and only limited RT should therefore be
adopted as adjuvant to chemotherapy in this category of
patients. 
In the advanced disease, it is evident from retrospective
studies that elderly patients without limiting co-morbidi-
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ties can benefit, with acceptable toxicity, from convention-
al chemotherapy with 6 courses of ABVD or doxorubicin-
containing regimens and that remission and relapse rates
are comparable to those of younger patients.59-61 At vari-
ance, the analysis of a sub-group of patients older than 65
years recruited into the HD9 GHSG trial (HD9 elderly)
showed that baseline BEACOPP produced a 21% death
rate due to severe toxicity.62 Regimens more intensive than
ABVD are difficult to tolerate in advanced age and should
therefore be avoided, even in patients with no limiting co-
morbidities. As far as bleomycin is concerned, a higher rate
of pulmonary toxicity was reported in patients older than
40 years compared to younger patients by the CALGB
(38% vs. 22%) and the Mayo Clinic (33% vs. 11).39,63 A
thorough evaluation and surveillance of respiratory func-
tion is recommended before and during ABVD chemother-
apy in elderly patients, and caution should be used when
administering growth factors during bleomycin-containing
chemotherapy. Regimens with reduced intensity com-
pared to ABVD are better tolerated; however, this advan-
tage is counterbalanced by the lower remission rate and
the higher relapse rate compared to standard dose regi-
mens.57,64 Reduced-intensity chemotherapy, with or with-
out limited RT, should be adopted in patients older than 80
years, as well as in those with severe co-morbidities (frail
patients), where the most sensible goal of therapy should
be to preserve a good quality of life with a palliative
approach. 
Recommendations
• Elderly patients with early-stage disease and no limiting co-
morbidities should receive a short chemotherapy regimen with
ABVD (2-4 courses) followed by involved field radiotherapy
[grade C].
• Elderly patients with advanced disease and no limiting co-
morbidities should be treated with 6 courses of ABVD [grade C]
• Patients older than 65 years should not receive the BEA-
COPP regimen (either baseline or escalated) due to its relevant
toxicity [grade B].
• Elderly patients with limiting co-morbidities (frail) should be
treated with reduced-intensity chemotherapy regimens or with a
palliative approach to preserve a good quality of life [grade C].
Evaluation of response and monitoring
Patients should be restaged after the completion of
first-line therapy. As a rule, all sites involved at the diag-
nosis should be restaged with appropriate methods.
Physical examination and volumetric CT scan remain the
cornerstones of the evaluation of response to therapy.
The FDG-PET has recently been added as a sensitive tool
for the assessment of response to first-line therapy. A sys-
tematic review of 13 studies for a total of 408 patients
indicated that FDG-PET has a sensitivity of 84% (CI: 71-
92) and a specificity of 90% (CI: 84-94) in detecting viable
tumor after therapy.65 The timing of FDG-PET is critical
because post-therapy inflammatory changes may persist
for two to three months after irradiation; to minimize the
impact of confounding factors, FGD-PET should there-
fore be done at least two weeks after the end of
chemotherapy and eight to 12 weeks after the completion
of RT.11,66 Moreover, in advanced Hodgkin’s lymphoma,
early FDG-PET evaluation after two cycles of chemother-
apy has recently proved to be highly predictive of out-
come and to be independent from the IPS variables.67,68
Therefore, the EP suggests that early FDG-PET be done to
evaluate response to CT; even though data on the out-
come of a PET-oriented therapy are not yet available.
Besides, the FDG-PET scan is recommended as part of
response evaluation at the end of treatment, if residual
masses are present. For the definition of CR, masses of
any size are permitted if they are FDG-PET negative after
therapy.11,66
As to CR monitoring, the EP addressed the issues of
timing for visits, blood count and biochemistry, and of
modalities of follow-up. No consensus was reached on
the utility of FDG-PET in the follow-up because of the
possibility that fibrosis, granulomatosis or unrelated neo-
plastic conditions may be responsible for false FDG-PET
positivity, as documented in patients with mediastinal
lymphoma.69 On the whole, the EP reached a consensus
on the following recommendations.
Recommendations
• Early evaluation of response (i.e. after 2 courses of ABVD)
with FDG-PET scan is suggested, even though a treatment
approach based on early FDG-PET findings cannot yet be recom-
mended outside of a clinical trial setting [grade C].
• Patients in complete remission should receive complete blood
count and physical examination every 3-4 months for the first two
years, every six months for the next three years and every 12
months until at least ten years from the end of treatment [grade C].
• Patients in complete remission should receive neck-chest-
abdominal-pelvic CT every six months for two years, then annu-
ally up to five years from the end of treatment, and depending on
clinical circumstances, thereafter [grade C].
• Annual breast cancer screening is recommended in patients
older than 35 years who were given radiotherapy above the
diaphragm [grade C].
• Cardiovascular monitoring is recommended for all patients
[grade C].
• Monitoring of thyroid function (FT3, FT4, TSH) is recom-
mended in patients treated with neck irradiation [grade C].
• Reproductive counseling is recommended [grade C].
Therapy of relapsed and resistant disease
About 20-25% of patients with advanced Hodgkin’s
lymphoma do not achieve a complete remission with up-
front standard chemotherapy (primary resistant disease),
and a proportion of remitters are expected to relapse at dif-
ferent time intervals from complete remission. It has long
been observed that the length of remission after first-line
therapy has a significant effect on the success of subse-
quent salvage treatment; therefore, relapses are defined as
early if they occur within 12 months from remission or late
when they occur beyond this term. The choice of the best
salvage approach should rely on the evaluation of prognos-
tic factors and clinical characteristics of patients. The issues
addressed by the Panel concerned the efficacy of second-
line conventional dose chemotherapy in resistant and
relapsing patients, the role of high-dose chemotherapy fol-
lowed by autologous stem cell transplant (ASCT), and the
role of allogeneic hemopoietic stem cell transplant (allo
HSCT). The role of RT in limited residual disease was also
addressed. 
The role of conventional-dose chemotherapy
Conventional-dose chemotherapy has virtually no cura-
tive potential in patients with resistant or early relapsing
Hodgkin’s lymphoma.70,71 In contrast, patients with a late
relapse may be sensitive to conventional-dose CT, and re-
treatment with initial chemotherapy may produce a sec-
ond complete remission.72,73 In patients with early relapse
or resistant to up-front therapy, the role of conventional-
dose CT as salvage therapy is two-fold: to achieve a max-
imum tumor reduction before high-dose chemotherapy
(debulking), and to efficiently mobilize progenitor cells
into peripheral blood (PBPC) for subsequent autologous
rescue. Conventional dose chemotherapy can also be used
in patients who are not candidates for ASCT because of
age and/or poor performance status. Several regimens of
different intensity and toxicity have been developed; the
more widely utilized include DHAP74 (cisplatin, high-dose
cytarabine and dexametasone), ICE75 (ifosfamide, carbo-
platin, etoposide), and IGEV76 (ifosfamide, gemcitabine,
vinorelbine). No randomized studies are available compar-
ing the relative efficacy of these different regimens. 
The role of high-dose chemotherapy followed by
autologous hemopoietic stem cell transplant
Evidence for the superiority of high-dose therapy fol-
lowed by autologous stem cell transplant over convention-
al-dose therapy in young (less than 60 years) patients with
relapsing and refractory disease has come from two ran-
domized studies carried-out by the British National
Lymphoma (BNLI) group and the European Blood and
Marrow Transplantation (EBMT) group, respectively.77,78 In
the BNLI trial, patients were treated with conventional
dose mini-Beam (carmustine, etoposide, cytarabine, and
melphalan) or high-dose BEAM with autologous stem cell
transplant; the actuarial 3-year event-free survival was sig-
nificantly better in patients who received high-dose thera-
py (53% vs. 10%). In the EBMT trial, patients relapsed
after chemotherapy were randomly assigned to four
courses of mini-Beam+dexamethasone (dexa-mini-Beam)
or two courses of dexa-mini-Beam followed by BEAM and
ASCT; the final analysis showed that FFP was significant-
ly higher in the BEAM+ASCT group (55% vs. 34%).
However, in neither of these two studies was an overall
survival advantage observed for the transplant group.
Non-randomized studies comparing autograft to conven-
tional salvage therapy include the Stanford experience,73
with a 4-year progression-free survival of 52% and 19%
for transplant and standard dose chemotherapy, respec-
tively, and the French Transplant Registry case-control
study79 with a 6-year PFS of 25% for transplant versus no
survival for conventional chemotherapy. The reduction of
transplant-related mortality (TRM) from the 10-15% of
early experiences to less than 3% of recent studies, has led
to a widespread acceptance of high-dose chemotherapy
followed by autologous stem cell transplantation as stan-
dard of care for patients with relapsed or primary resistant
Hodgkin’s lymphoma. In all experiences, the outcome of
patients receiving ASCT for relapsed disease is significant-
ly better than that of patients with primary refractory dis-
ease and the number of lines of therapy before the trans-
plant adversely affects its outcome. Eligibility criteria
include age less than 65 years and absence of concomitant
diseases that can be precipitated by the high-dose proce-
dure. Mature results of ASCT in first relapse indicate a PFS
ranging from 45% to 77%, with an OS from 50 to 80%;80-
84 results are significantly better when a second remission
or a minimal disease status is achieved before ASCT, and
demonstrate that ASCT is able to cure more than half of
the patients in first chemosensitive relapse. As to the tim-
ing, the ASCT should be performed at first relapse, with
the possible exception of patients with a late (more than
three years after remission), and/or a single site (docu-
mented by FDG-PET, if available) relapse who can do as
well with conventional dose chemotherapy. 
The role of allogeneic hemopoietic stem cell transplant 
Allogeneic HSCT was first explored in selected individ-
uals with advanced Hodgkin’s lymphoma,85,86 and proved
that some patients, who had failed many lines of therapy,
did survive long-term. One explanation for this result, is
the combined anti-tumor effect of CT and RT with the
immunologic effect of the graft-versus-lymphoma reac-
tion. Four studies have reported the results of myeloabla-
tive allogeneic HSCT in Hodgkin’s lymphoma, respective-
ly from Seattle,85 the International Bone Marrow
Transplant Registry,86 the Johns Hopkins University,87 and
the European Group for Blood and Marrow
Transplantation.88 The total number of patients reported is
373, with a cumulative incidence of TRM of 52%. The OS
is 44%, and the PFS 20%, with a 57% relapse rate, despite
the use of high-dose chemotherapy and radiotherapy. 
The development of reduced intensity conditioning reg-
imens (RIC) in the late 90s provided a new opportunity to
use allo HSCT in Hodgkin’s lymphoma. Several studies
have been published on the outcome of patients receiving
allo HSCT after RIC regimens;89-94 the main results are
illustrated in Table 6. As shown by a recent direct compar-
ison,95 RIC transplants are associated with a significantly
lower TRM compared to myeloablative transplants, with
a 10% improvement in PFS and OS; nonetheless, the risk
of relapse still remains a problem. Best results are obtained
in patients with a Karnofsky score greater than 80 and a
chemosensitive disease; this observation raises the issue of
considering an allogeneic HSCT before the end stage of
the disease. Results of transplants from HLA identical sib-
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Table 6. Results of the reduced intensity conditioning allogeneic stem cell
transplantation.
Institutions N. of Early Cumulative PFS OS Relapse Ref. #
pts TRM % TRM % % % %
EBMT, 2002 311 17 27 26 46 64 89
UKCG, 2005 49 4 16 39 55 43 90
MDAH, 2005 58 2 15 32 64 55 91
SPCP, 2006 40 12 25 32 48 92
GITMO, 2007 32 3 3 32 81 93
FHCRC, 2007 27 11 39 18 51 47 94
Total 485 8 21 29 49 62
TRM: transplant-related mortality; PFS: progression-free survival; OS: overall survival.
EBMT: European group for Blood and Marrow Transplantation; UKCG: United Kingdom
Cooperative Group.MDAH: M.D.Anderson Hospital; SPCP: Spanish Cooperative Panel;
GITMO: Gruppo Italiano Trapianto Midollo Osseo; FHCRC: Fred Hutchinson Cancer Research
Center.
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lings, unrelated donors and haploidentical family members
are comparable,94 with the evidence of a graft-versus-
Hodgkin effect that can be beneficial in terms of PFS.95
The role of radiotherapy for limited residual disease
Radiotherapy may have a role as salvage in stages IA-IIA,
when failure is limited to the initial nodal sites of disease
(documented by the FDG-PET, if available), and prior RT
has not been delivered on the area. In addition, RT (30-36
Gy) to residual nodal disease may be recommended in
patients with a very good partial response after first-line
chemotherapy with ABVD, Stanford V or BEACOPP regi-
mens for advanced disease, and in patients with residual
disease after salvage therapy with ASCT. In primary refrac-
tory disease, RT may have only a palliative role. 
Recommendations
• Patients younger than 60-65 years, with relapsed disease or
refractory to first-line therapy should receive a second-line
chemotherapy for debulking, followed, in chemosensitive patients,
by high-dose chemotherapy and the infusion of autologous stem
cells from peripheral blood or bone marrow [grade A].
• Second-line chemotherapy should consist of non cross-resist-
ant regimens such as IGEV, DHAP, ICE, or other ifosfamide -
and/or cytarabine-containing chemotherapy [grade B].
• It is recommended that the patient and family be screened for
HLA identical or partially identical donors. The search for an
unrelated donor is recommended in patients for whom a suitable
family donor is not available [grade D].
• An allogeneic stem cell transplant is recommended in patients
relapsing after an autologous transplant and in patients refracto-
ry to 1-2 lines of therapy or with early relapses, who failed to col-
lect a suitable number of autologous stem cells from peripheral
blood and bone marrow. A reduced-intensity conditioning is rec-
ommended and peripheral blood stem cells are to be preferred to
bone marrow [grade C].
• Reduction of tumor mass is recommended before the prepara-
tive regimen for an allogeneic transplant [grade C].
• A myeloablative conditioning regimen is not recommended as
standard approach, but it may be considered in selected young
patients with primary refractory disease [grade C].
• For patients relapsing more than three years after first com-
plete remission, prognostic factors such as stage of disease at
relapse or systemic symptoms are to be considered to make a deci-
sion between conventional dose chemotherapy or high-dose
chemotherapy followed by autologous stem cell transplant [grade
D].
• Radiotherapy can be recommended for limited residual nodal
disease in patients with a very good partial response after 6-8
courses of chemotherapy [grade B] or with residual nodal disease
after ASCT [grade D].
Fertility preservation
Fertility may be transiently or permanently affected by
cancer treatment. Infertility is a late effect of great impor-
tance as it influences different domains of survivorship.96
Therefore, a guidance about fertility preservation methods
and related issues in people treated for Hodgkin’s lym-
phoma is warranted. Two large studies have recently ana-
lyzed this problem in men97 and women98 treated for
Hodgkin’s lymphoma. The EORTC study analyzed fertili-
ty in male patients treated with various combinations of
radiotherapy and chemotherapy, with or without alkylat-
ing agents, or with radiotherapy alone for early-stage
Hodgkin’s lymphoma. Follicle-stimulating hormone (FSH)
plasma levels were measured at least 12 months after the
end of treatment to assess post-treatment potential fertili-
ty. The proportion of elevated FSH was 3% and 8% in
patients treated with radiotherapy only or with non-alky-
lating-containing chemotherapy such as ABVD or EBVP,
and 60% in those treated with alkylating-containing regi-
mens such as MOPP or BEACOPP. The GHSG analyzed
the menstrual status in a large cohort of women treated
with BEACOPP regimen (either baseline or escalated) for
advanced disease and the influence on amenorrhea of age
and use of oral contraceptives during chemotherapy.
Amenorrhea was significantly more frequent after dose-
escalated BEACOPP compared to standard BEACOPP, in
women older than 30 years and in those who did not take
oral contraceptives during chemotherapy. The EP
addressed the issues of which information patients should
receive about their fertility potential after therapy for
Hodgkin’s lymphoma and of which fertility preservation
techniques should be adopted in fertile patients before the
initiation of therapy. The literature review found many
cohort studies, case series and case reports, but relatively
few randomized or definitive trials examining the success
and the impact of fertility preservation methods. The Panel
noted that the infertility risk is in most studies reported as
rate of azoospermia or amenorrhea, even though these are
only surrogate measures of infertility.
Patient counseling
All patients of fertile age who are candidates to
chemotherapy and/or radiotherapy for Hodgkin’s lym-
phoma must be advised of the risk that treatment can per-
manently impair fertility. The EP recommended that the
most recent data on the potential gonadic damage of ther-
apy be clearly illustrated to the patients. In particular, male
patients candidate to the ABVD chemotherapy (a
chemotherapy without alkylating agents) should know
that oligospermia may occur in less than 10%, with full
recovery in almost all of them; female patients should
expect amenorrhea to occur in about 5%, with recovery in
about 75% of them, according to the age (almost full
recovery in patients younger than 30 years). Patients candi-
date to chemotherapy containing alkylating agents and
procarbazine such as baseline or dose-escalated BEACOPP,
should know that the risk of azoospermia is about 90%,99
with no difference between patients treated with baseline
versus dose-escalated BEACOPP, and that of continuous
amenorrhea more than 50%.98 Candidates to high-dose
chemotherapy and hemopoietic stem cell transplant (either
autologous or allogeneic) should be warned that this
approach may be quite gonadotoxic and that premature
ovarian failure is less prevalent when patients are condi-
tioned with reduced-intensity regimens.100 At the same
time, the prospective measures that can be taken to limit
the risk of gonadic damage should be illustrated. The EP
recommendations are in accordance with those recently
forwarded by the American Society of Clinical Oncology
on fertility preservation in cancer patients.101
Fertility preservation in men
The EP reviewed available data on the different meas-
ures to preserve fertility in men. These measures include
sperm cryopreservation, testicular hormonal suppression
and testicular tissue cryopreservation. The available evi-
dence indicates that sperm cryopreservation is an effective
method of fertility preservation.101-103 The sperm must be
collected before the initiation of treatment and the multi-
ple samples generally needed to collect a suitable sperm
quantity should not substantially delay the initiation of
chemotherapy. Sperm quality may be poor in advanced
Hodgkin’s disease with systemic symptoms, even before
treatment.104 Nonetheless, even men with reduced sperm
count and motility may be candidates for sperm cryop-
reservation because the modern techniques of assisted
reproduction may not require a large quantity of sperm to
be successful.101 In contrast, gonadoprotection through
hormonal suppression is not effective in preventing steril-
ity induced by chemotherapy.105 Although this conclusion
is drawn from small studies and the experience in
Hodgkin’s lymphoma is scanty, the EP agreed that hor-
monal therapy is not able to preserve fertility in men who
are treated with gonadotoxic drugs such as the alkylating
agents. Testicular tissue or spermatogonial cryopreserva-
tion and transplantation are still in their very early phase
of experimentation and can not, at the moment, be recom-
mended. 
Fertility preservation in women
The EP reviewed available data on the different meas-
ures to preserve fertility in women. These measures
include ovarian suppression, and oocyte or ovarian tissue
cryopreservation. There is not yet any conclusive evidence
regarding the efficacy and safety of ovarian suppression
through oral contraceptives and/or gonadotropin-releasing
hormone (GnRH) as a method to maintain fertility in
women during chemotherapy. Data are mostly derived
from small observational studies with menstruation, not
fertility, as end-point measure. Some of these studies
report resumption of menses and/or pregnancies after
ovarian suppression.106,107 A GHSG study has investigated
the menstrual status in a large series of women treated
with different protocols for early and advanced stage dis-
ease,98 and conclusively observed that amenorrhea was
most pronounced in patients who had not taken oral con-
traceptives during chemotherapy. Oocyte cryopreserva-
tion requires sustained ovary stimulation before oocyte
harvesting. This technique exposes patients to short-term
high estrogen levels during the stimulation and may sub-
stantially delay the initiation of chemotherapy. Also, the
overall pregnancy rate after this procedure is, at the
moment, very low and further research is needed to
improve its efficiency. Ovarian tissue cryopreservation
does not require ovarian stimulation and follicles can be
cryopreserved with good efficiency.101 There have been
reports of live births from ovarian transplantation.108
However, experience with this technique is still very lim-
ited and it can only be prospected as a forthcoming proce-
dure. 
If pelvic irradiation is part of the therapeutic program (in
cases of primary subdiaphragmatic Hodgkin’s lymphoma),
the ovaries should be surgically or laparoscopically moved
away from the field of irradiation (oophoropexy) during
RT and repositioned after the end of treatment. The over-
all success rate of this procedure in preserving menstrual
function is about 50%.109
The EP concluded that there is uncertain evidence of the
efficacy of ovarian suppression to preserve fertility and
still insufficient experience on forthcoming options such
as ovarian or oocyte cryopreservation. 
Recommendations
• Fertile patients should be informed of the potential fertility
damage produced by chemotherapy and/or radiotherapy [grade
D].
• Male patients should be offered sperm cryopreservation as a
measure to preserve their fathering potential [grade D].
• Female patients should be offered estro-progestinic therapy to
reduce the risk of amenorrhea and oocyte or ovary tissue cryop-
reservation to reduce the risk of infertility (still an experimental
procedure) [grade D].
• Female patients should be advised to adopt effective contra-
ceptive methods in order to avoid pregnancies in the three years
after the end of chemotherapy [grade D].
Discussion
This paper provides practice guidelines for the clinical
management of patients with classical Hodgkin’s lym-
phoma. Recommendations are issued that cover a large
domain including decisions on which tests and evalua-
tions are to be performed before therapy, how to approach
first-line therapy, how to evaluate the response, how to
monitor patients after therapy, and how to treat refracto-
ry and relapsed patients. Recommendations on fertility
preservation are also provided. Literature was retrieved
from January 1995 to June 2008 in a systematic manner
according to explicit criteria for quality and strength, and a
panel of experts used a literature systematic review to
compare specific therapies. However, in the process of
guideline production, interpretation of evidence, consen-
sus on its grading, and consensus on clinical key questions
not supported by good evidence played a critical role. The
theoretical value of the experts consensus approach to
influence clinical practice is the assumption that knowl-
edgeable experts have an implicit and comprehensive
mastery of scientific and practical information that would
yield the most appropriate recommendations. The result is
that 5 out of the 35 recommendations were supported by
level 1 scientific evidence and received grade A, while 11
were supported by consensus only and were explicitly
marked with a grade D. 
A comparison and summary of currently available evi-
dence-based guidelines on Hodgkin’s lymphoma is shown
in Table 7. Since recommendations for the initial work-up
of patients before treatment are largely based on the clini-
cal practice of panelists and are not supported by high-
level evidence, somewhat different approaches have been
envisioned. These apply particularly to the selection of
patients in whom a bone marrow biopsy may be manda-
tory as initial work-up, to the use of CT scan of the neck
to detect nodal involvement, and to the use of left ventric-
ular ejection fraction before and after therapy to evaluate
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cardiac co-morbidity or toxicity. As far as FDG-PET is con-
cerned, this technology may play a role in the staging of
Hodgkin’s lymphoma and could have an impact on the ini-
tial treatment choice. The NCCN (National
Comprehensive Cancer Network) guidelines110 recom-
mend the use of whole body FDG-PET scan in the initial
work-up of patients with Hodgkin’s lymphoma to define
the extent of disease, especially if CT scan is equivocal. On
the other hand, the ESMO (European Society of Medical
Oncology) guidelines111 do not recommend FDG-PET scan
among the initial staging procedures. The present SIE-SIES-
GITMO guidelines indicate that baseline FDG-PET scan is
recommended, even though not mandatory, and empha-
size the utility of early FDG-PET re-evaluation after a short
ABVD chemotherapy to prospectively discriminate
patients responsive to therapy and expected to have a
durable remission. 
As far as early stage therapy is concerned, all the avail-
able guidelines agree on recommending a combined
modality approach with a short ABVD chemotherapy, fol-
lowed by radiotherapy on involved nodal areas (Table 7).
Based on the EORTC and GHSG trials, the number of
cycles of ABVD is defined according to risk factors and the
irradiation dose ranges between 20 and 30 Gy (with a pos-
Table 7. A comparison between recommendations of the different available guidelines (first part).
Guidelines ESMO 2008 NCCN 2008 SIE-SIES-GITMO
Initial work-up
• Abdomen CT scan • Complete hemogram • Complete hemogram, 
• Liver biopsy, if elevated • ESR, LDH, albumin, BUN, creatinine • Liver and renal function tests
alkaline phosphatase or  • Chest X-ray • LDH, albumin 
any other clinical suspicion • CT scan of thorax abdomen, and pelvis • ESR 
• Bone marrow biopsy • Whole body FDG-PET scan • Chest X-ray
• Bone marrow biopsy in stages • CT scan of the neck,
IB, IIB, III, and IV thorax, abdomen and pelvis
• Pregnancy test • Left ventricular ejection fraction
• Bone marrow biopsy in patients
In selected cases: with systemic symptoms or abnormal
• Neck CT scan hemogram
• HIV serology • Baseline FDG-PET or 
• Left ventricular ejection fraction CT-PET recommended,
although not mandatory
• Thyroid function tests and dental care
in candidates to neck irradiation 
• Pregnancy test
• Fertility counseling
First-line therapy
Favorable < 3 nodal areas, no bulk, no symptoms Stage IA-IIA non bulky EORTC criteria 
early disease • ABVD × 2 courses • ABVD x 2 to 4 courses • ABVD × 3 to 4 courses + IF-RT (30 Gy)
+ IF-RT (30 Gy) + IF-RT (30 Gy) or • ABVD × 2 courses + IF-RT (20 Gy)
• Stanford V x 8 weeks +IF-RT (30 Gy) only in controlled clinical trials
Unfavorable ≥ 3 nodal areas, no Stage IA-IIA with bulk EORTC criteria 
early disease • ABVD × 4 courses • ABVD × 4 to 6 courses + IF-RT (30 Gy) or • ABVD x 4 to 6 courses + IF-RT (30 Gy)
+ IF-RT (30 Gy) • Stanford V × 12 weeks 
+ RT (30 Gy) on initial bulk or on residual
FDG-PET positive sites after CT
Stage IB-IIB, no bulk
• ABVD × 6 courses + IF-RT 
(30-36 Gy) on initial bulk ,or
• Stanford V ×12 weeks
+ RT (36 Gy) on initial 
sites >5 cm or on residual 
FDG-PET-positive sites 
after CT
First-line therapy for advanced disease
Patients ≤60 years Patients ≤60 years Patients ≤70 years
• BEACOPP escalated x 8 • ABVD x 6 courses or • ABVD x 6 to 8 courses
courses + RT (30 Gy) on • Stanford V x 12 weeks • First-line baseline or escalated
PET-positive residual disease + RT (36 Gy) on initial BEACOPP is not recommended outside
sites >5 cm or on clinical trials
Patients >60 years PET-positive residual disease • Baseline and escalated BEACOPP
• ABVD x 6-8 courses • Escalated BEACOPP (if IPS ≥4) should not be used in patients older than
+RT (30 Gy) on PET-positive x 4 courses, followed 65 years for toxicity
residual disease by baseline BEACOPP x 4 + RT
to initial sites > 5 cm, if CR at restaging
with PET-CT after 4 courses
• Escalated BEACOPP x 8 courses + 
RT to initial sites >5 cm, if PR at restaging
with PET-CT after 4 courses
continuing to next page.
sible 6 Gy boost on prior bulk). In the favorable group, the
number of courses of ABVD varies from two (ESMO
guidelines) to four (NCCN and SIE-SIES-GITMO guide-
lines), with 30 Gy IF-RT. In the NCCN guidelines, the
Stanford V program, in its 8-week version, is indicated as
an alternative option. In the unfavorable group, four cours-
es of ABVD are recommended by the ESMO and six by
the NCCN and the SIE-SIES-GITMO guidelines, with the
12-week Stanford V + RT on bulk or on FDG-PET positive
residual disease as an alternative option. The definition of
the unfavorable group, however, is not uniform between
the different guidelines and includes more than two nodal
sites and bulk in the ESMO, bulk and/or systemic symp-
toms in the NCCN and the EORTC criteria in the present
guidelines. 
Different recommendations have been devised in the
different guidelines as to the use of escalated BEACOPP
chemotherapy in advanced stage disease. According to the
ESMO guidelines, the evidence accumulated so far is suf-
ficient to recommend this therapy as a standard in patients
less than 60 years of age; indeed, escalated BEACOPP
chemotherapy has resulted in a higher overall response
rate, and a longer disease-free and overall survival com-
pared to the alternating COPP-ABVD43 and the baseline
BEACOPP.43 In a direct comparison with ABVD, however,
a superiority in terms of overall survival for BEACOPP has
not yet emerged.47,48 At variance with the ESMO, the
NCCN guidelines recommend escalated BEACOPP only
for high-risk patients with an IPS score ≥4 and the SIE-
SIES-GITMO guidelines conclude that, based on the cur-
rently available evidence, first-line escalated BEACOPP
therapy cannot be recommended as a standard, but only
evaluated in controlled clinical trials. These discrepancies
document that, despite the evidence-based nature of rec-
ommendations, there are intrinsic limitations in the
process of translating the evidence into practice recom-
mendations. In particular, the trade-offs between toxicity
and benefit or between quality of life and survival prolon-
gation, are subjective in nature and may change from one
panel to another. Recommendations on response evalua-
Guidelines for Hodgkin’s lymphoma
Table 7. A comparison between recommendations of the different available guidelines (second part).
Guidelines ESMO 2008 NCCN 2008 SIE-SIES-GITMO
Evaluation of response and monitoring
• At the end of treatment • At the end of treatment, • Neck, chest, abdomen and pelvis
with physical examination, lab tests with physical examination, CT and FDG-PET scan at 
and CT scan of all initially involved areas every 2 to 4 months for 1-2 years, the end of treatment
• FDG-PET scan capacity to then every 3 to 6 months for • Early evaluation of response
distinguish between active or non active the next 3-5 years with FDG-PET after 2 courses
tissue requires further confirmation • Complete hemogram of ABVD is suggested
in prospective trials ESR (if elevated at diagnosis), • Neck, chest, abdomen and pelvis CT
• Physical examination and lab tests chemistry profile every 2 to 4 scan (or total body CT-PET, if available)
should be performed every 3 months for 1-2 years, every 6 months for 2 years, then
months for the first year, then every 3 to 6 months annually up to 5 years after the
every 6 months in the 2nd and 3rd years for the next 3-5 years end of treatment, or depending on clinical
and once a year, thereafter. • TSH at least annually circumstances
• CT scan is mandatory to if RT to neck was given • Complete hemogram and
confirm a complete remission • Chest X-ray or CT physical examination every 3 to 4
• After RT involving breast tissue, scan every 6 to 12 months for the first 2 years,
women should be screened for months during first 2-5 years. every 6 months for the next 3 years
secondary breast cancer clinically • Abdominal and pelvic and every 12 months until the 10th
and by mammography CT scan every 6 to 12 year of follow-up 
(from the age of 40 years, onwards) months for first 2-5 years • Annual breast cancer screening
• Cardiovascular survey, is recommended in patients
breast self exam, and older than 35 years who were
skin cancer survey given RT involving breast tissue
• No routinely FDG-PET surveillance • Cardiovascular monitoring
• Fertility counseling • Thyroid monitoring is recommended
• Monitoring during the in patients who were given
first 5 years after therapy neck irradiation
to detect recurrences, then annually • Reproductive counseling
for the risk of late complications
Salvage therapy
Relapses After CT or CT+RT Relapses within 3 years from CR or refractory
• High-dose chemotherapy • Non cross-resistant • Debulking with a second-line 
and ASCT in young patients chemotherapy non cross-resistant chemotherapy,
• Gemcitabine alone or in • HDCT +ASCT followed, by high-dose chemotherapy and 
combination in patients • RT, in particular cases ASCT in chemosensitive patients, 
relapsing after ASCT After RT alone Relapses after 3 years from CR and fit elderly
• Allogeneic SCT in • Chemotherapy, as in • Standard-dose non cross resistant
chemosensitive young patients advanced stage disease chemotherapy (even with the same
with suitable donor (only in a regimen that produced first remission)
controlled trial setting) Relapses after ASCT
• Allogeneic stem cell tranplant after 
reduced intensity conditioning 
• Myeloablative allogeneic stem cell 
transplant in selected cases only
ASCT: autologous stem cell transplant; CR: complete remission; HDCT: high-dose chemotherapy; RT: radiotherapy.
E. Brusamolino et al. 
tion, monitoring and duration of follow-up are consistent
among the different guidelines and indicate the need for a
prolonged surveillance to monitor for late complications.
As far as FDG-PET scan is concerned, the ESMO guidelines
suggest that the capacity of this technology in the response
evaluation (distinguishing between active and non-active
residuals) requires prospective confirmation. The NCCN
guidelines discourage the use of FDG-PET in routine clini-
cal surveillance, and a consensus was not reached in the
SIE-SIES-GITMO guidelines on the utility of FDG-PET in
the follow-up because of the possibility of false positivity. 
The need for reproductive counseling is emphasized in
the NCCN guidelines, but only the SIE-SIES-GITMO
guidelines provide extensive recommendations to prospec-
tively limit the risk of therapy-related gonadic damage and
to preserve fertility. 
We believe that the therapeutic recommendations issued
in these guidelines could be greatly influenced by the clin-
ical trials that will be concluded in 2009 and 2010.
Therefore, the present guidelines are due to be be up-dated
by the end of 2010. 
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